Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.
The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...
The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...
Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...
The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...
Kisunla (donanemab-azbt) is a brand-name injection for IV infusion prescribed for Alzheimer’s disease. Kisunla has no known interactions with alcohol, other drugs, or supplements. However ...
Kisunla (donanemab-azbt) is a prescription drug used to treat Alzheimer’s disease. The drug is given as an intravenous (IV) infusion by a healthcare professional. You’ll typically receive a ...
New research suggests certain blood tests could help doctors diagnose Alzheimer's disease faster and more accurately.
GlobalData on MSN2d
Alzheimer’s heterogeneity necessitates diverse enrollment in clinical trialsClinical trials need to evolve screening criteria to include diverse patient groups as more Alzheimer's disease drugs become ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback